In summary, this study demonstrated that switching to degludec from other basal insulins was associated with significantly reduced rates of overall hypoglycemia with improved glycemic control and treatment satisfaction for patients with T1D or T2D in routine clinical practice. Here, INS is linked to type 2 diabetes mellitus.